Home > Press > Cosmographics Pvt. Ltd Signed LOI to Acquire All the Interest of AT-GC Biopharm
Avanti Therapeutics, Inc. announced that Cosmographics Pvt. Ltd (CPL) has signed a letter of intent to acquire 100% of the interest of its manufacturing operation subsidiary, AT-GC BioPharm, a biopharmaceutical manufacturing company headquartered in Baltimore, Maryland.
Cosmographics Pvt. Ltd Signed LOI to Acquire All the Interest of AT-GC Biopharm
Baltimore, MD. And Mumbai, India | Posted on November 3rd, 2007
Avanti Therapeutics, Inc. announced that Cosmographics Pvt. Ltd (CPL) has signed a letter of intent to acquire 100% of the interest of its manufacturing operation subsidiary, AT-GC BioPharm, a biopharmaceutical manufacturing company headquartered in Baltimore, Maryland. The company believes that the acquisition will expand CPL's presence in the biopharmaceutical manufacturing capacity by utilizing AT-GC BioPharm's well established intelligent manufacturing platform licenses and logistic facilities. The acquisition would also add direct outsourcing channels into small and mid sized biopharmaceutical companies in the region.
According to the letter of intent, CPL would use its internal available resource to complete the acquisition. "We are very happy to see this acquisition could take place," said Sunil Majmundar, CEO of Cosmographics Pvt. Ltd. "It would significantly improve our current manufacturing platforms and widen our product lines in the near future."
"The acquisition will help us develop new nanotechnology based technology platforms to accelerate our current drug development pipeline for cancer and infectious diseases" according to Dr. Arkesh Mehta, CEO of Avanti Therapeutics. Dr. Tracy Tucker, Director of R&D at Avanti Therapeutics is optimistic that the transaction will help in developing silica based nanoparticles with core-shell architecture that will be used to accelerate biomarker monitoring and targeted drug delivery of therapeutics.
About Avanti Therapeutics, Inc.
AT-GC BioPharm is an emerging biopharmaceutical company dedicated to the discovery and development of innovative technologies for rapidly advancing knowledge based manufacturing of biopharmaceutical products for consistent quality. AT-GC BioPharm is uniquely able to develop innovative technologies by accelerating and enhancing the process development skills and experience of proven drug manufacturing processes with world-class, proprietary process development technologies developed in collaboration with their partners. AT-GC BioPharm has established an exclusive worldwide strategic alliance with Avanti Therapeutics to develop and commercialize novel drug compounds for the treatment of infectious diseases and cancer. The company operates globally with headquarters in Clarksburg, Maryland, USA, and major offices in Baltimore, MD., Oxford, UK, and Mumbai, India. To learn why more and more biopharmaceutical companies trust AT-GC BioPharm as their preferred process development partner, visit http://www.at-gc.com .
Safe Harbor Statement
Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
For more information, please click here
Attn.: Jenny Smith
Tel: +1 (301) 540-5474
Cosmographics, Pvt. Ltd.
Attn: S Majmundar
Tel: 91 2516-9310 and
Avanti Therapeutics, Inc.
Copyright © 2007 PR-USA.net
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Taking the guesswork out of cancer therapy: New molecular test kit predicts patientís survival and drug response August 1st, 2014
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014
New imaging agent provides better picture of the gut July 30th, 2014
Zenosense, Inc. July 29th, 2014
Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014
President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014
Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014
Air Forceís 30-year plan seeks 'strategic agility' August 1st, 2014
Keysight Technologies Begins Operations August 1st, 2014
Bruker Announces Acquisition of High-Speed, 3D Super-Resolution Fluorescence Microscopy Company Vutara July 28th, 2014
Malvern Instruments completes acquisition of MicroCal and announces purchase of Archimedes product from Affinity Biosensors July 25th, 2014
Nanotechnology merger - temicon and holotools join forces July 8th, 2014